Navigation Links
Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies

RESEARCH TRIANGLE PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX News Network) -- Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. Antonella Perotti, MD, Istituto Nazionale dei Tumori Milano, SENDO Foundation, an investigator in Adherex's European Phase Ib/II study of single-agent ADH-1, will present data today from that study at the 5th International Symposium on Targeted Anticancer Therapies in Amsterdam, The Netherlands.

The data includes 30 patients who received an aggregate of over 200 doses (68 cycles) of ADH-1 given on a weekly schedule with doses ranging from 150 to 2400 mg/m2. ADH-1 was well tolerated at all doses tested for periods of up to eight months, displayed predictable pharmacokinetics, and demonstrated hints of anti-tumor activity in five patients with advanced, chemotherapy-resistant cancer. A maximum tolerated dose was not defined.

"This European data is consistent with our prior clinical experience, showing ADH-1 to be well tolerated over a broad dosage range with hints of anti-tumor activity in a variety of tumor types," said William P. Peters, MD, PhD, Chairman and CEO of Adherex. "Given the unexpected level of synergy of ADH-1 in combination with chemotherapy that we have reported from our preclinical studies, the clinical development of this drug continues fully on track. We expect to have results from the North American Phase II trial with single-agent ADH-1 as well as initial results from our ongoing Phase I combination studies with ADH-1 and chemotherapy available later this year."

In the European Phase Ib/II study, three of 19 patients (16%) with ovarian/gynecological tumors experienced evidence of anti-tumor activity, one with an unconfirmed partial response (previously reported) and two with prolonged stabilization of their disease, which were previously
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... Nov. 24, 2014  Pifflers United Chronic and ... the release of results of a study of ... the self-management of fibromyalgia pain. The results demonstrated ... pain, very significant clinically meaningful pain reduction can ... members with fibromyalgia used ActiPatch® for 7 days ...
(Date:11/23/2014)... DAYTON, N.J. , Nov. 23, 2014  Aurobindo ... lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count ... been found to contain some empty capsules. ... resulting in adverse health consequences that could range from ... withdrawal effect, or status epilepticus (long period seizures) that ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - ... develops new uses for previously approved drugs and new molecular ... Cast on Thursday, January 26, 2012 at 4:15 EST. The ... on the company,s progress and a press release on January ...
... DIEGO, Jan. 5, 2012 Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... for the removal of filter cake in drilling operations.  ... acts as a barrier to hydrocarbon flow on the ...
Cached Medicine Technology:Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 2Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 3Verenium Launches Second Enzyme Product for Oilfield Services 2Verenium Launches Second Enzyme Product for Oilfield Services 3
(Date:11/24/2014)... The Healthy Skin Care Journal, a ... skin care products, recently announced its launch. Located on ... wide variety of articles, tips, and evaluations about popular ... alternatives. , According to Emily Lataille, the website’s main ... thoroughly researched reviews, tips for the skin, and information ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Abington ... Ternopolska, MD has joined The Neurology Group and ... Multiple Sclerosis Center. , A graduate of Vinnica ... Neurology at Albert Einstein Medical Center in Philadelphia and ... Jaffe Multiple Sclerosis Center at Weill Cornell Medical College. ...
(Date:11/24/2014)... 24, 2014 Recently, SweetDressy.com, a well-known ... its new collection of 2014 Evening Dresses. All these ... to the company’s marketing manager, the special offer is ... for more. , Sweetdressy.com has been working well in ... unveil the latest designs. Their new dresses may be ...
(Date:11/24/2014)... Houston, TX (PRWEB) November 24, 2014 ... in all of the wrong ingredients. Consistently consuming a ... body to develop stores of excess fat that typically ... health problems and rearing its ugly head in the ... , When dieters make the decision to rid ...
(Date:11/24/2014)... Dr. Michael Kettel , a leading fertility ... NBC to discuss egg freezing as a viable and increasingly ... the news recently, with new company benefits at Facebook and ... , “[The companies] see it as a way to take ... path.” Says Dr. Kettel. , Up until a few weeks ...
Breaking Medicine News(10 mins):Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3
... place again in the,Texas Medical Center as Houston-based LifeGift ... and one of a handful in the nation --,with ... work,in that facility is expected to help save the ... "This building will provide us to the opportunity ...
... Fifth Third Bank,today announced a strategic alliance with ... revenue cycle management services to,the healthcare industry, that ... for healthcare providers. The alliance,will enable Fifth Third ... from,claims to payments -- and integrate the data ...
... ,Renovis, Inc. (Nasdaq: RNVS ), a biopharmaceutical ... for major medical needs in the areas of,neurological ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... Trade Commission,requesting additional information with regard to the ...
... Some antioxidants may protect people like athletes, soldiers from fatal ... The key to curing heat stroke may have been found ... to suffer a deadly rise in body temperature, according to ... the April 4 issue of Cell , also suggest ...
... with genital and nipple piercings, also known as intimate piercings, ... about them, according to a new article in the journal ... such discussions do not occur, even when treating infections and ... uneasiness over this increasingly common form of body art. An ...
... 2008 Care Net,President Melinda Delahoyde spoke out Thursday ... "How tragic that,these two young girls felt that secretly ... President Melinda Delahoyde. "We are saddened they,didn,t receive help ... that,exist in Houston to offer hope and assistance to ...
Cached Medicine News:Health News:Houston-Based LifeGift Becomes State's Only Stand-Alone Organ and Tissue Recovery Agency 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 2Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 3Health News:Tragedies Point to Need for Pregnancy Centers, Care Net Says 2
... PDCs computer-generated Thermal Printing Wristbands and ... direct thermal and thermal transfer printers. ... activate a heat-sensitive thermal coating under ... printers use heat to transfer highly ...
... Wristbands and Tags print in mere ... transfer printers. Direct thermal printers use ... coating under the bands protective surface. ... transfer highly durable ink from a ...
... coded patient identification bracelets (wristbands) and/or ... at patient care areas throughout the ... identification and in creating a positive ... back to the patient through the ...
... secure band is desired for adults and where an ... appropriate. The design allows for two bands to be ... on the wrist and the second to be held ... This is particularly useful in a hospital situation wherea ...
Medicine Products: